Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy

@inproceedings{Danila2008AbirateroneAA,
  title={Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy},
  author={Daniel Costin Danila and Dana E. Rathkopf and Michael J Morris and Susan F. Slovin and Lawrence H. Schwartz and K. Chip Farmer and Aseem Anand and Christopher M Haqq and Martin Fleisher and Howard I. Scher},
  year={2008}
}
5019 Background: A proportion of CRPC overexpress androgen synthetic enzymes and are dependent on androgens for growth. Abiraterone acetate (AA) inhibits 17 α-hydroxylase and C17,20-lyase to decrease serum androgen to undetectable levels. Methods: AA plus prednisone was studied in Pts with metastatic CRPC who had progressed on docetaxel based chemotherapy. Pts received oral AA 1000 mg QD, and prednisone 5 mg BID in 28 day cycles. The primary endpoint a >50% decline in PSA from baseline. Changes… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

New options for the management of castration-resistant prostate cancer: a case perspective.

  • Dawn Goetz
  • Medicine
  • Journal of the National Comprehensive Cancer Network : JNCCN
  • 2011

Experience with fulvestrant acetate in castration-resistant prostate cancer patients.

VIEW 1 EXCERPT
CITES BACKGROUND